Compounds > 2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine
Page last updated: 2024-09-04

2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine and Hemorrhage

2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine has been researched along with Hemorrhage in 3 studies

*Hemorrhage: Bleeding or escape of blood from a vessel. [MeSH]

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Cutlip, DE; Gibson, CM; Kereiakes, DJ; Kirtane, AJ; Mehran, R; Mihatov, N; Secemsky, EA; Song, Y; Steg, PG; Yeh, RW; Zhao, B1
Harris, J; Johnson, TW; Lasserson, D; Loke, YK; Mahadevan, K; Mumford, A; Pouwels, K; Pufulete, M; Reeves, BC1
Gargiulo, G; Valgimigli, M1

Trials

1 trial(s) available for 2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine and Hemorrhage

ArticleYear
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe
    Open heart, 2022, Volume: 9, Issue:2

    Topics: Acute Coronary Syndrome; Adolescent; Aspirin; Clopidogrel; Cohort Studies; Dinucleoside Phosphates; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor

2022

Other Studies

2 other study(ies) available for 2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine and Hemorrhage

ArticleYear
Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT Study.
    Cardiovascular revascularization medicine : including molecular interventions, 2022, Volume: 41

    Topics: Dinucleoside Phosphates; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Treatment Outcome

2022
Deciding on the Duration of Dual Antiplatelet Therapy-When the Choice Between 2 Evils Is Still Evil.
    JAMA cardiology, 2017, 05-01, Volume: 2, Issue:5

    Topics: Dinucleoside Phosphates; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Stents

2017